Clover Health Investments (CLOV) Projected to Release Quarterly Earnings on Wednesday

Clover Health Investments (NASDAQ:CLOV) is expected to issue its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of $0.0386 per share and revenue of $728.2660 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Clover Health Investments (NASDAQ:CLOV) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). The company had revenue of $749.19 million for the quarter, compared to the consensus estimate of $714.89 million. Clover Health Investments had a negative net margin of 2.58% and a negative return on equity of 16.52%.

Clover Health Investments Price Performance

CLOV stock opened at $4.17 on Monday. The company has a 50-day simple moving average of $4.58 and a 200 day simple moving average of $3.11. The company has a market capitalization of $2.20 billion, a P/E ratio of -34.75 and a beta of 2.41. Clover Health Investments has a fifty-two week low of $1.58 and a fifty-two week high of $5.59.

Insider Activity at Clover Health Investments

In other news, VP Joseph Frank Oldakowski sold 12,102 shares of Clover Health Investments stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $4.86, for a total value of $58,815.72. Following the transaction, the vice president directly owned 299,067 shares of the company’s stock, valued at $1,453,465.62. This trade represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Andrew Toy sold 313,476 shares of Clover Health Investments stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $5.32, for a total transaction of $1,667,692.32. Following the transaction, the chief executive officer owned 9,609,825 shares in the company, valued at approximately $51,124,269. The trade was a 3.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 715,884 shares of company stock valued at $3,202,372. Corporate insiders own 23.51% of the company’s stock.

Hedge Funds Weigh In On Clover Health Investments

Institutional investors and hedge funds have recently bought and sold shares of the business. Alliancebernstein L.P. lifted its position in shares of Clover Health Investments by 1.2% in the third quarter. Alliancebernstein L.P. now owns 415,985 shares of the company’s stock worth $1,273,000 after purchasing an additional 5,085 shares in the last quarter. Allworth Financial LP increased its stake in Clover Health Investments by 218.9% in the 3rd quarter. Allworth Financial LP now owns 9,509 shares of the company’s stock valued at $29,000 after buying an additional 6,527 shares during the period. Verition Fund Management LLC increased its stake in Clover Health Investments by 11.3% in the 4th quarter. Verition Fund Management LLC now owns 65,777 shares of the company’s stock valued at $155,000 after buying an additional 6,677 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Clover Health Investments in the 1st quarter worth approximately $37,000. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Clover Health Investments during the 2nd quarter valued at $31,000. Hedge funds and other institutional investors own 19.77% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CLOV shares. Wall Street Zen upgraded shares of Clover Health Investments from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Canaccord Genuity Group increased their price target on Clover Health Investments from $4.20 to $5.50 and gave the company a “buy” rating in a research note on Tuesday, July 21st. UBS Group lifted their target price on Clover Health Investments from $2.75 to $4.75 and gave the stock a “neutral” rating in a report on Thursday, June 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Clover Health Investments in a research report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Clover Health Investments currently has a consensus rating of “Hold” and a consensus target price of $4.25.

Clover Health Investments Company Profile

Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.

At the core of Clover’s offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.